A new Big Ten Cancer Research Consortium phase II study will test the combination of gedatolisib and talazoparib in advanced triple-negative or BRCA 1/2-mutated HER2-negative breast cancer in men and women.
Breast cancer is the most common cancer in women, with more than 266,000 new cases in 2018. Breast cancer in men is less common, with more than 2,400 new cases annually. About 15 percent of all invasive breast cancers diagnosed in the United States each year are triple-negative. Triple-negative breast cancers don’t express the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2). Inherited gene mutations in BRCA1 or 2 are responsible for about 5 to 10 percent of breast cancers in the United States.
People with advanced triple-negative breast cancer have fewer treatment options and the primary treatment for triple-negative breast cancer is chemotherapy. Exploring non-chemotherapy options for treatment may uncover new ways to treat this disease.
The goal of the study, BTCRC-BRE18-337, “Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers,” is to identify the safe doses for combining gedatolisib and talazoparib, and to assess the efficacy of the combination. Read More
Jan. 24, 2020: Nataliya Uboha, MD, PhD, assistant professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, presented a poster highlighting the Big Ten Cancer Research Consortium’s BTCRC-GI18-149 study during the American Society of Clinical Oncology’s 2020 Gastrointestinal Cancers Symposium in San Francisco. The poster, titled “Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma” was presented during Trials in Progress Poster Session A on Thursday, Jan. 23, 2020. See abstract.... Read More
Jan. 23, 2020: Hirva Mamdani, MD, assistant professor of medicine in the Thoracic Oncology and Phase I Therapeutics Program and a medical oncologist at the Barbara Ann Karmanos Cancer Institute and Wayne State University, will present a poster highlighting the Big Ten Cancer Research Consortium’s BTCRC-ESO14-012 study during the American Society of Clinical Oncology’s 2020 Gastrointestinal Cancers Symposium, Thursday, Jan. 23-25, from noon – 1:30 pm and 4:45-5:45 p.m. PT at the Moscone West Building in San Francisco, CA. The poster, titled “Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium... Read More
Jan. 22, 2020: The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has joined the Big Ten Cancer Research Consortium (Big Ten CRC). The Big Ten CRC was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. Its membership now includes the cancer centers of all Big Ten universities. Located in Baltimore, Md., UMGCCC offers innovative approaches to diagnosing and treating all types of cancer, conducts cutting-edge research to bring the latest advances in cancer treatment directly to... Read More
Jan. 21, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights the fact that cancer does not discriminate and can affect even the most active and fit individuals. We also recognize the hard work researchers are doing and the grants they are receiving to improve our understanding of cancer and how to treat it. Read More
Jan. 21, 2020: Veronika Bachanova, MD, PhD, associate professor of medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota, has been appointed to represent the University of Minnesota on the Big Ten Cancer Research Consortium Steering Committee. The Steering Committee is composed of one researcher from each Big Ten CRC member institution and meets on a regular basis to review activities of the consortium and decide matters of policy. The Steering Committee determines the criteria for approving concepts for development with the Big Ten CRC. Read More
Jan. 17, 2020: Pictured from left: Sneha Phadke, DO, University of Iowa, co-investigator of BTCRC-BRE18-337; Oana Danciu, MD, University of Illinois at Chicago, sponsor-investigator of BTCRC-BRE15-016; Kari Wisinski, MD, University of Wisconsin, sponsor-investigator of BTCRC-BRE18-337 and co-investigator of BTCRC-BRE15-016.Big Ten cancer researchers presented two Big Ten Cancer Research Consortium (Big Ten CRC) studies during the 2019 San Antonio Breast Cancer Symposium in December. In a poster session, investigators reported on safety results from BTCRC-BRE15-016, a phase 2 study of palbociclib in combination with Tamoxifen as first line therapy for... Read More
Jan. 7, 2020:Investigator Spotlight: Benjamin Teply, MD, University of Nebraska Medical Center Research interests: I am a medical oncologist engaged in clinical and translational research in genitourinary malignancies, with a special focus in prostate cancer. I have worked on novel treatment strategies for prostate cancer, with a focus on mechanisms other than suppression of androgen signaling, in both treatment-naïve (such as PARP inhibition) and castration-resistant prostate cancer (such as therapeutic high-dose testosterone). I am also dedicated in optimizing the use of approved therapies to maximize patient benefit. Read More
Dec. 3, 2019: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) congratulates researchers who recently received grants to continue their work to fight against cancer. We also zoom in on the work researchers are doing to understand and treat breast cancer both during and after surgery and/or treatment. Read More
Nov. 13, 2019: H. Rex Gaskins, PhD, associate director for education at the Cancer Center at Illinois (CCIL) and Keith W. and Sarah M. Kelly Professor of Immunophysiology at University of Illinois at Urbana-Champaign, has been appointed to represent the university on the Big Ten Cancer Research Consortium (Big Ten CRC) Steering Committee. As a collaboration among Big Ten universities, the Big Ten CRC leverages the scientific and clinical expertise of its members by developing and conducting early phase oncology clinical trials. In 2018, CCIL established itself as a research institute on the Urbana-Champaign campus... Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube